Braest Cancer, Dry Eye
Conditions
Keywords
corneal changes, breast cancer, hormonal treatment
Brief summary
Aromatase inhibitors (AI) therapy is the treatment of choice for estrogen receptor-positive breast cancer (BC). While AIs effectively suppress tumor growth, estrogen deprivation may have negative impacts on the eyes. This work evaluated the anterior segment changes in estrogen-dependent BC after hormonal treatment.
Detailed description
Aromatase inhibitors (AI) therapy is an important treatment for estrogen receptor-positive breast cancer (BC). This work evaluated the eye anterior segment changes in estrogen-dependent BC after hormonal treatment. This cross-sectional study was conducted on female patients aged ≥18 who received treatment for BC. Patients were evaluated by a number of tests to determine the effects on the cornea and the lacrimal system
Interventions
hormonal treatment for breast cancer
Sponsors
Sohag University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Females diagnosed with breast cancer
Exclusion criteria
* uncontrolled diabetes , auto immune diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| tear break up time test and shirmer test | 6 months | these tests done before starting treatment and in follow up after recieving treatment to evaluate the lacrimal function and dry eye |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Corneal thickness and endothelium hexagonality | 6 months | Corneal thickness and hesagonality were evaluated before and after treatment with aromatase inhibitors |
Countries
Egypt
Outcome results
None listed